Sunedison Slumps As Bronte Capital Goes Long
Sunedison shares slipped by as much as 1.81% to $7.05 per share today in spite of a blog post from Bronte Capital’s John Hempton revealing that his firm has taken a long position. Indeed, it’s a very...
View ArticleFlotek’s Data ‘Made Up’ Or ‘Rigged’: Bronte Capital
Flotek shares tumbled today in early trading after John Hempton of Bronte Capital published a blog post saying that the firm’s data just doesn’t work and “looks like it was made up or at least...
View ArticleHempton Nails Flotek Industries Call
Whitney Tilson on Flotek Industries’ stock price drop and the accuracy of the companies FracMax® data analytics via an email he sent to investors. Boy, you don’t see this every day. John Hempton of...
View ArticleHempton: We are short some previously high flying shale companies
John Hempton‘s Bronte Capital February letter Our results this month are good. The Amalthea fund had the benefit of a falling Australian dollar but the underlying portfolio still performed...
View ArticleBronte Capital Amalthea Fund Letter: Valeant is not a normal short; Walking...
Bronte Capital Amalthea Fund letter to investors for the month ended February 29, 2016. Bronte Capital Amalthea Fund had a good month in a stressful market. Our performance is usually good in a weakly...
View ArticleThe Fraught Life Of A Dumpster-Diving U.S. Short-Seller [Podcast]
Short-selling, the practice of betting against stocks by agreeing to sell equities that you don’t own, has been in the headlines recently. The share price of Valeant Pharmaceuticals International Inc....
View ArticleJohn Hempton: Valeant Pharmaceuticals (VRX) Is Headed Towards ZERO
John Hempton’s battle against Valeant Pharmaceuticals (VRX) is not over yet. In his latest letter to investors the founder of Bronte Capital recaps the pharma company’s problems. Although Hempton has...
View ArticleClik here to view.
John Hempton On The Perils Of Shorting
John Hempton, founder and CIO of Bronte Capital and one of Australia’s best-known hedge fund managers....
View ArticleClik here to view.
Bronte Capital Goes Short On Nu Skin Enterprises, Inc.
Nu Skin Enterprises, Inc. (NYSE:NUS) has gotten a bad review from Bronte Capital for what John Hempton calls “wonky accounts.” In a blog post on the firm’s website, Hempton said today that he is “short...
View ArticleClik here to view.
Bronte Up 15% YTD; Notes “Insanity” On ChiNext
Bronte Capital Management Amalthea Fund Investors’ Letter forMarch2015 The fund was up and beat the global index by a percent in March. More generally though, markets remain at elevated levels –...
View Article
